PRVB

Provention Bio Inc.

Price

return (12m)

p/e

-11.30

p/bv

15.32

DIVIDEND YIELD

0.00%

PRVB price

Provention Bio

If you had invested

exposure

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

Return on Investment PRVB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

ago, you would now have:

Fundamentals PRVB

Valuation

P/E

-11.30

Sector -3.50

Industry -3.50

P/BV

15.32

Sector 2.02

Industry 2.02

P/Revenue (PSR)

Sector 2.01

Industry 2.01

EV/EBITDA

-24.38

Sector -214.99

Industry -214.99

EV/EBIT

-24.29

Sector -47.59

Industry -47.59

P/EBITDA

-12.99

Sector -21.41

Industry -21.41

P/EBIT

-12.87

Sector -28.65

Industry -28.65

P/Total Assets

7.88

Sector 1.19

Industry 1.19

P/Net Current Assets

Sector -11.97

Industry -11.97

P/Working Capital

Sector -167.95

Industry -167.95

EPS

-2.21

Sector -1.81

Industry -1.81

BVPS

1.63

Sector 2.06

Industry 2.06

Efficiency

Gross Margin

96.40%

Sector 41.30%

Industry 41.30%

EBITDA Margin

-582.90%

Sector -17,117.21%

Industry -17,117.21%

EBIT Margin

-585.15%

Sector -4,185,659.35%

Industry -4,185,659.35%

Operating Margin

-100.00%

Sector -35.21%

Industry -35.21%

Net Profit Margins

-100.00%

Sector -35.91%

Industry -35.91%

Asset Turnover

0.05

Sector 0.02

Industry 0.02

Profitability

ROE

-135.59%

Sector -56.04%

Industry -56.04%

ROA

-69.76%

Sector -60.31%

Industry -60.31%

ROIC

Sector -2,335.95%

Industry -2,335.95%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

Sector 2.89

Industry 2.89

Net Debt / EBITDA

2.00

Sector -14,066,680.10

Industry -14,066,680.10

Net Debt / EBIT

1.99

Sector -8.06

Industry -8.06

Net Debt / Equity

-1.16

Sector -33,024.69

Industry -33,024.69

Gross Debt / Equity

0.19

Sector -0.85

Industry -0.85

Equity/Assets

0.51

Sector 0.46

Industry 0.46

Liabilities/Assets

0.51

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

631.41%

Sector -

Industry -

5Y Earnings CAGR

7.62%

Sector -

Industry -

Fundamentals PRVB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price (US$)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
PRVB Provention Bio Inc.	$0.00	-	0.00%	-11.30	15.32	-135.59%	-100.00%
JNJ Johnson & Johnson	$269.33	55.44%	1.96%	30.82	7.63	24.76%	21.48%
PFE Pfizer Inc.	$27.49	22.33%	6.26%	35.85	1.83	5.11%	6.86%
ABBV AbbVie Inc.	$263.93	23.34%	2.59%	73.99	-78.76	-106.44%	9.81%
NVO Novo Nordisk A/S	$43.19	-26.70%	4.29%	10.56	5.61	53.11%	35.32%
MRK Merck & Co. Inc.	$146.11	87.14%	2.31%	113.21	8.55	7.55%	4.76%
AZN AstraZeneca PLC	$166.35	9.78%	1.94%	19.88	5.12	25.77%	16.95%
BMY Bristol-Myers Squibb Company	$62.71	43.77%	4.04%	13.67	5.68	41.55%	18.85%
ZTS Zoetis Inc.	$72.66	-49.60%	2.88%	11.47	9.64	84.02%	27.77%
AMGN Amgen Inc.	$383.04	43.28%	2.60%	23.66	17.70	74.80%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$784.44	31.54%	0.47%	18.63	2.54	13.65%	27.86%
HALO Halozyme Therapeutics Inc.	$111.35	46.87%	0.00%	31.57	90.97	288.13%	24.86%
MCK McKesson Corporation	$874.67	27.00%	0.38%	19.57	-26.84	-137.16%	1.29%
VRTX Vertex Pharmaceuticals Incorporated	$506.08	30.72%	0.00%	29.15	6.34	21.76%	35.00%
CAH Cardinal Health Inc.	$224.45	52.89%	0.91%	30.53	-19.32	-63.29%	0.68%
ARGX argenx SE	$994.44	35.42%	0.00%	2.24	2.63	117.11%	44.68%
HRMY Harmony Biosciences Holdings Inc.	$42.23	31.71%	0.00%	13.50	2.45	18.14%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

ago, you would now have:

*This calculation reflects price variation only.

PRVB Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT Provention Bio

Provention Bio Inc.

Average Investor10 user rating

4.0 (0 people)

United States

10 years

Founded: 2016

2018

Time since IPO - 8 years

59

Employees

Provention Bio Inc. (United States) is listed on the Nasdaq and has a market capitalization of $1.87 billion, with shareholders equity totaling $121.85 million.

The company employs approximately 59 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Provention Bio Inc. reported $14.22 million in revenue, generating net income of $-165.22 million.

Key financial metrics include a P/E ratio of -11.30, a price-to-book (P/B) ratio of 15.32, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker PRVB.

Market cap

$1.87 billion

Net worth

$121.85 million

$121,849,000.00

Assets

$236.86 million

$236,856,000.00

Total Shares Outstanding

74.72 million

74,723,000

Average Daily Trading Volume

$3.01 million

$3,010,093.32

Sector

Health Care

Industry

Biotechnology

PRVB

PRVB revenue and profits

Financial Results PRVB

DRAG THE FRAME TO SEE MORE DATA

PRVB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$874.67 25,76% (12M)

P/E

19.57

0.38%

ROE

-137.16%

P/BV

-26.84

CAH - Cardinal Health

$224.45 51,61% (12M)

P/E

30.53

0.91%

ROE

-63.29%

P/BV

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12M)

P/E

30.82

1.96%

ROE

24.76%

P/BV

7.63

ABBV - AbbVie

$263.93 22,42% (12M)

P/E

73.99

2.59%

ROE

-106.44%

P/BV

-78.76

MRK - Merck & Co.

$146.11 85,19% (12M)

P/E

113.21

2.31%

ROE

7.55%

P/BV

8.55

AZN - AstraZeneca

$166.35 9,17% (12M)

P/E

19.88

1.94%

ROE

25.77%

P/BV

5.12

PFE - Pfizer

$27.49 22,43% (12M)

P/E

35.85

6.26%

ROE

5.11%

P/BV

1.83

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$874.67 25,76% (12 M)

P/L

19.57

0.38%

ROE

-137.16%

P/VP

-26.84

CAH - Cardinal Health

$224.45 51,61% (12 M)

P/L

30.53

0.91%

ROE

-63.29%

P/VP

-19.32

JNJ - Johnson & Johnson

$269.33 56,33% (12 M)

P/L

30.82

1.96%

ROE

24.76%

P/VP

7.63

ABBV - AbbVie

$263.93 22,42% (12 M)

P/L

73.99

2.59%

ROE

-106.44%

P/VP

-78.76

MRK - Merck & Co.

$146.11 85,19% (12 M)

P/L

113.21

2.31%

ROE

7.55%

P/VP

8.55

AZN - AstraZeneca

$166.35 9,17% (12 M)

P/L

19.88

1.94%

ROE

25.77%

P/VP

5.12

PFE - Pfizer

$27.49 22,43% (12 M)

P/L

35.85

6.26%

ROE

5.11%

P/VP

1.83

Frequently Asked Questions

What is the price of Provention Bio (PRVB) today?

A cotação de Provention Bio (PRVB) hoje está em US$ 0.00, com uma variação de 0% em relação ao último ano. A cotação de Provention Bio (PRVB) iniciou o ano negociando na casa dos US$ 0.00 e hoje está em US$ 0.00. Acompanhe o gráfico de cotação em tempo real, a cotação histórica de Provention Bio (PRVB) e dados de ações do Ibovespa e mercados internacionais.

Quando Provention Bio (PRVB) paga dividendos?

Provention Bio (PRVB) não distribuiu dividendos no último ano.

Is Provention Bio (PRVB) a good investment?

Atualmente, Provention Bio (PRVB) está cotada a US$ 0.00, com um P/L de -11.30, representando um desvio de -1,130% em relação ao seu P/L médio histórico. No último ano, a ação apresentou uma variação de 0 em sua cotação e distribuiu US$ 0.00 em dividendos, resultando em um Dividend Yield de 0.00%. O retorno total do acionista foi de 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Provention Bio (PRVB) stock?

Investir em ações de Provention Bio (PRVB) pode ser feito de duas formas: comprando a stock uma empresa estrangeira e é atrelado ao dólar.

How much would 100 shares of Provention Bio (PRVB) yield today?

A rentabilidade de Provention Bio (PRVB) foi de 0.00% no último mês, 0.00% no último ano e 0.00% nos últimos 5 anos (já considerando valorização e dividendos).

Nos últimos 12 meses, a empresa pagou um total de US$ 0.00 em dividendos, um Dividend Yield de 0.00%.

Se você quisesse comprar 100 ações de Provention Bio (PRVB) hoje, o investimento total seria de US$ 0.00, com base na cotação atual de US$ 0.00.

Based on historical performance, the investment would have grown to approximately:

Em 1 ano: US$ 0.00
Em 5 anos: US$ 0.00
Em 10 anos: US$ 0.00

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

PRVB

Provention Bio Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment PRVB

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING PRVB WITH OTHER STOCK

current DY: 0.00%

5-year average DY: 0.00%

ABOUT Provention Bio

Provention Bio Inc.

United States

10 years

2018

59

PROFIT X PRICE PRVB

Financial Results PRVB

PRVB cash flow

Asset, Revenue and Profit Growth - PRVB

PRVB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

PFE - Pfizer

Frequently Asked Questions